Clinical Trial Detail

NCT ID NCT02251821
Title JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Fred Hutchinson Cancer Research Center
Indications

myelofibrosis

Therapies

Fludarabine

Tacrolimus

Mycophenolate mofetil

Busulfan

Pacritinib

Momelotinib

Melphalan

Methotrexate

Ruxolitinib

Cyclophosphamide

Age Groups: senior adult

No variant requirements are available.